Zhao Ruihong, Lu Juan, Shi Yu, Zhao Hong, Xu Kaijin, Sheng Jifang
Department of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
J Int Med Res. 2018 Mar;46(3):1138-1145. doi: 10.1177/0300060517735231. Epub 2017 Dec 6.
Liver cirrhosis is a health problem worldwide, and ascites is its principal symptom. Refractory ascites is intractable and occurs in 5%-10% of all patients with ascites due to cirrhosis. Refractory ascites leads to a poor quality of life and high mortality rate. Ascites develops as a result of portal hypertension, which leads to water-sodium retention and renal failure. Various therapeutic measures can be used for refractory ascites, including large-volume paracentesis, transjugular intrahepatic portosystemic shunt, vasoconstrictive drugs, and an automated low-flow ascites pump system. However, ascites generally can be resolved only by liver transplantation. Because not all patients can undergo liver transplantation, traditional approaches are still used to treat refractory ascites. The choice of treatment modality for refractory ascites depends, among other factors, on the condition of the patient.
肝硬化是一个全球性的健康问题，腹水是其主要症状。顽固性腹水难以治疗，在所有肝硬化腹水患者中占5%-10%。顽固性腹水会导致生活质量下降和死亡率升高。腹水是由门静脉高压引起的，门静脉高压会导致水钠潴留和肾衰竭。多种治疗措施可用于治疗顽固性腹水，包括大量腹腔穿刺放液、经颈静脉肝内门体分流术、血管收缩药物和自动低流量腹水抽吸系统。然而，腹水一般只有通过肝移植才能得到解决。由于并非所有患者都能接受肝移植，因此仍采用传统方法治疗顽固性腹水。治疗顽固性腹水的方式选择除其他因素外，还取决于患者的病情。
